(Q35911679)

11 August 2017

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib (English)

1 reference

11 August 2017

hepatocellular carcinoma

1 reference

2

Josep M Llovet

1 reference

11 August 2017

Augusto Villanueva

1

1 reference

PMCID

3336075

11 August 2017

language of work or name

English

0 references

publication date

21 February 2012

1 reference

11 August 2017

Clinical Cancer Research

1 reference

11 August 2017

18

1 reference

11 August 2017

7

1 reference

11 August 2017

1824-1826

1 reference

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Targeted therapies for hepatocellular carcinoma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Sorafenib in advanced hepatocellular carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Design and endpoints of clinical trials in hepatocellular carcinoma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

Shifting paradigms: the seeds of oncogene addiction

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3336075

10.1158/1078-0432.CCR-12-0151

24 September 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

PMCID

3336075